Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization
关键词
抽象
描述
Twenty consecutive patients (30 eyes) with subfoveal PM-CNV, 9 of whom had been unsuccessfully treated with Visudyne PDT, were treated with IVT of 0.5mg ranibizumab. ETDRS best corrected visual acuity, macular thickness on OCT scans, and angiographic features were recorded and evaluated. The aspect of OCT scans passing across the PM-CNV was also analyzed. IVTs were repeated only in case of persistent angiographic leakage and if OCT scans showed retinal thickening or edema and serous retinal detachment. The follow-up period was at least 6 months
日期
| 最后验证: | 12/31/2013 |
| 首次提交: | 12/30/2013 |
| 提交的预估入学人数: | 01/08/2014 |
| 首次发布: | 01/09/2014 |
| 上次提交的更新: | 01/08/2014 |
| 最近更新发布: | 01/09/2014 |
| 实际学习开始日期: | 09/30/2013 |
| 预计主要完成日期: | 10/31/2014 |
| 预计完成日期: | 10/31/2014 |
状况或疾病
干预/治疗
Drug: Aflibercept injection
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Experimental: Aflibercept injection Myopic eyes with retinal neovascularization submitted a aflibercept intravitreal injection | Drug: Aflibercept injection Aflibercept intravitreal injection |
资格标准
| 有资格学习的年龄 | 21 Years 至 21 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - Myopic and CNVM Exclusion Criteria: - Patients with poor compliance - Patients with uncontrolled diabetes and hypertension or any other medical condition that increase the risk of complications like recent history of Stroke or myocardial infraction (< one year). (Physician clearance was obtained for all patients). - Age related macular degeneration with Juxtafoveal and Subfoveal CNVM: Recurrent CNVM following PDT and TTT with IVTA. Patient who could not afford PDT, Macugen or Lucentis which is FDA approved. - Patients who had undergone major surgery 28 days before, were excluded from the study and it was also suspended prior to elective surgery. - Refractory macular oedema due to vein occlusion, Pseudophakia, Clinically significant macular oedema (CSME) etc. that affects vision and does not respond adequately to usual treatment methods. - Proliferative diabetic retinopathy, non-resolving vitreous haemorrhage with PDR. - Idiopathic CNVM, Inflammatory CNVM and other conditions associated with CNVM. |
结果
主要结果指标
1. Efficacy [To evaluate the clinical results of aflibercept intravitreal injection (AII) in choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV), after 1 year follow up.]
次要成果指标
1. Safety and Tolerability [To evaluate the clinical results of aflibercept intravitreal injection (AII) in choroidal neovascularization (CNV) secondary to pathologic myopia (PM-CNV), after 1 year follow up.]
